Gene targeting in human pluripotent stem cells with adeno-associated virus vectors

被引:38
|
作者
Mitsui, Kaoru [1 ]
Suzuki, Keiichiro [1 ]
Aizawa, Emi [1 ]
Kawase, Eihachiro [2 ]
Suemori, Hirofumi [3 ]
Nakatsuji, Norio [2 ,4 ]
Mitani, Kohnosuke [1 ]
机构
[1] Saitama Med Univ, Gene Therapy Div, Res Ctr Genom Med, Saitama 3501241, Japan
[2] Kyoto Univ, Inst Frontier Med Sci, Dept Dev & Differentiat, Sakyo Ku, Kyoto 6068507, Japan
[3] Kyoto Univ, Inst Frontier Med Sci, Lab Embryon Stem Cell Res, Stem Cell Res Ctr,Sakyo Ku, Kyoto 6068507, Japan
[4] Kyoto Univ, Inst Integrated Cell Mat Sci, Sakyo Ku, Kyoto 6068507, Japan
关键词
Human embryonic stem cells; Human induced pluripotent stem cells; Adeno-associated virus vectors; Homologous recombination; Hypoxanthine phosphoribosyl transferase 1; NANOG; EXPRESSION; LOCUS; MOUSE; LINES; IDENTIFICATION; INDIVIDUALS; INTEGRATION; SEROTYPES;
D O I
10.1016/j.bbrc.2009.08.075
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human pluripotent stem cells, such as embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs), have the ability to differentiate into various cell types, and will become a potential source of cellular materials for regenerative medicine. To make full use of hESCs or hiPSCs for both basic and clinical research, genetic modi. cation, especially gene targeting via homologous recombination (HR), would be an essential technique. This report describes the successful gene targeting of the hypoxanthine phosphoribosyl transferase 1 (HPRT1) and the NANOG loci in human pluripotent stem cells with adeno-associated virus (AAV) vectors. At the HPRT1 locus, up to 1% of stable transformants were targeted via HR with an AAV-HPRT1 targeting vector, without loss of pluripotency. On the other hand, 20-87% of stable transformants were targeted using an AAV-NANOG-targeting vector designed for the promoter-trap strategy. In the KhES-3 cell line, which shows particularly high fragility to experimental manipulation, gene targeting was successful only by using an AAV vector but not by electroporation. In addition to hESC, gene targeting was achieved in hiPSC lines at similar frequencies. These data indicate that AAV vectors may therefore be a useful tool to introduce genetic modi. cations in hESCs and hiPSCs. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:711 / 717
页数:7
相关论文
共 50 条
  • [1] GENE TARGETING WITH ADENO-ASSOCIATED VIRUS VECTORS
    Russell, David W.
    JOURNAL OF GENE MEDICINE, 2011, 13 (7-8): : 415 - 415
  • [2] Directed Evolution of Adeno-associated Virus for Enhanced Gene Delivery and Gene Targeting in Human Pluripotent Stem Cells
    Asuri, Prashanth
    Bartel, Melissa A.
    Vazin, Tandis
    Jang, Jae-Hyung
    Wong, Tiffany B.
    Schaffer, David V.
    MOLECULAR THERAPY, 2012, 20 (02) : 329 - 338
  • [3] Gene targeting in vivo by adeno-associated virus vectors
    Miller, Daniel G.
    Wang, Pei-Rong
    Petek, Lisa M.
    Hirata, Roli K.
    Sands, Mark S.
    Russell, David W.
    NATURE BIOTECHNOLOGY, 2006, 24 (08) : 1022 - 1026
  • [4] Gene targeting in vivo by adeno-associated virus vectors
    Daniel G Miller
    Pei-Rong Wang
    Lisa M Petek
    Roli K Hirata
    Mark S Sands
    David W Russell
    Nature Biotechnology, 2006, 24 : 1022 - 1026
  • [5] Design and packaging of adeno-associated virus gene targeting vectors
    Hirata, RK
    Russell, DW
    JOURNAL OF VIROLOGY, 2000, 74 (10) : 4612 - 4620
  • [6] Gene Targeting at Silent Loci with Adeno-Associated Virus Vectors
    Li, B. Li
    Deyle, David R.
    Russell, David W.
    MOLECULAR THERAPY, 2013, 21 : S101 - S102
  • [7] Adeno-associated virus vectors for human gene therapy
    Haifeng Chen
    World Journal of Medical Genetics, 2015, (03) : 28 - 45
  • [8] Receptor targeting of adeno-associated virus vectors
    Büning, H
    Ried, MU
    Perabo, L
    Gerner, FM
    Huttner, NA
    Enssle, J
    Hallek, M
    GENE THERAPY, 2003, 10 (14) : 1142 - 1151
  • [9] Receptor targeting of adeno-associated virus vectors
    H Büning
    M U Ried
    L Perabo
    F M Gerner
    N A Huttner
    J Enssle
    M Hallek
    Gene Therapy, 2003, 10 : 1142 - 1151
  • [10] Targeting of recombinant adeno-associated virus vectors
    Hallek, M
    Büning, H
    Ried, M
    Perab, L
    Kofler, D
    Gerner, F
    Wendtner, CM
    Leike, K
    Huttner, N
    Hutter, M
    CANCER GENE THERAPY, 2001, 8 (09) : 688 - 688